Leading Insulin Doesn't Heighten Cancer Risk, Studies Find
15:54 EDT 11 Jun 2012 | Wall Street Journal
Four studies involving Sanofi SA's Lantus, the top-selling insulin in the U.S., appeared to blunt concerns that it might cause cancer.
Original Article: Leading Insulin Doesn't Heighten Cancer Risk, Studies Find
More From BioPortfolio on "Leading Insulin Doesn't Heighten Cancer Risk, Studies Find"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
